Through targeting HIF-2α, VEGFR1 and/or VEGFR2, these six miRNAs could deplete the drug targets of HIF-2α inhibitors and/or VEGFR-TKIs, explaining inferior outcomes of anti-angiogenic therapies in m-ccRCC. This evidence concerns the gene FLT1 and nonpapillary renal cell carcinoma.